Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled, Loaded Phase III Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

NCT05679479 is registered in ClinicalTrials.gov with Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd as lead sponsor.

NCT NCT05679479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05679479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-controlled, Loaded Phase III Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
Lead sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Phase
Phase 3
Overall status
Completed
Start date
January 19, 2024
Completion date
April 18, 2024
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19